155 related articles for article (PubMed ID: 25952738)
1. ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Marcus C; Marashdeh W; Ahn SJ; Taghipour M; Subramaniam RM
J Nucl Med; 2015 Jul; 56(7):989-94. PubMed ID: 25952738
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.
Marcus C; Paidpally V; Antoniou A; Zaheer A; Wahl RL; Subramaniam RM
J Nucl Med; 2015 Feb; 56(2):204-8. PubMed ID: 25613535
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
[TBL] [Abstract][Full Text] [Related]
4. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years.
Paidpally V; Tahari AK; Lam S; Alluri K; Marur S; Koch W; Wahl RL; Subramaniam RM
J Nucl Med; 2013 Dec; 54(12):2039-45. PubMed ID: 24101687
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival.
Marcus C; Antoniou A; Rahmim A; Ladenson P; Subramaniam RM
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):281-8. PubMed ID: 25676871
[TBL] [Abstract][Full Text] [Related]
6. Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.
Antoniou AJ; Marcus C; Tahari AK; Wahl RL; Subramaniam RM
J Nucl Med; 2014 Jul; 55(7):1062-8. PubMed ID: 24777290
[TBL] [Abstract][Full Text] [Related]
7. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
8. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.
Taghipour M; Sheikhbahaei S; Trahan TJ; Subramaniam RM
Nucl Med Commun; 2016 Jun; 37(6):602-8. PubMed ID: 27110955
[TBL] [Abstract][Full Text] [Related]
9. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up
Taghipour M; Marcus C; Sheikhbahaei S; Mena E; Prasad S; Jha AK; Solnes L; Subramaniam RM
J Nucl Med; 2017 May; 58(5):737-743. PubMed ID: 27811123
[TBL] [Abstract][Full Text] [Related]
10. The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin's lymphoma.
Taghipour M; Marcus C; Jones S; Sarangi R; Trahan TJ; Subramaniam RM
Nucl Med Commun; 2016 Jul; 37(7):699-704. PubMed ID: 26990623
[TBL] [Abstract][Full Text] [Related]
11. The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma.
Taghipour M; Marcus C; Califano J; Fakhry C; Subramaniam RM
J Med Imaging Radiat Oncol; 2015 Dec; 59(6):681-6. PubMed ID: 26768092
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.
Sheikhbahaei S; Mena E; Marcus C; Wray R; Taghipour M; Subramaniam RM
J Nucl Med; 2016 Jun; 57(6):855-60. PubMed ID: 26837337
[TBL] [Abstract][Full Text] [Related]
14. Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management.
Taghipour M; Marcus C; Nunna P; Subramaniam RM
Clin Nucl Med; 2016 Feb; 41(2):e93-7. PubMed ID: 26545018
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
17. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
19. Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning.
Miyake KK; Nakamoto Y; Togashi K
Ann Nucl Med; 2012 Jul; 26(6):492-500. PubMed ID: 22492392
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients.
Cervino AR; Pomerri F; Alfieri R; Sileni VC; Castoro C; Galuppo S; Evangelista L
Nucl Med Commun; 2014 Feb; 35(2):160-8. PubMed ID: 24220054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
